UK Pharmaceuticals and Healthcare Market <br />BMI View: The UK's health technology assessment and pricing/reimbursement decision making bodies are <br />looking to take an increasingly hard line when determining whether a new drug provides added value to <br />patients compared with existing therapies. However, with regards to the incoming value-based medicine <br />pricing system, we believe that providing a satisfactory definition of the word 'value' will be difficult and <br />companies will be faced with a challenging pricing environment. In the past, the National Institute for <br />Health and Care Excellence (NICE) has come under attack for its definition of cost effectiveness. <br />Headline Expenditure Projections <br />http://www.marketreportsonline.com/322612.html .
